SCHEMBL7056562

SCHEMBL7056562

O=C(O)c1ccc2c(c1)nc(-c1ccc(-c3cccc(OCC(=O)N4CCCCC4)c3)cc1)n2C1CCCCC1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.50
CPT1A P50416 6/20 0.46
ACHE P22303 1/20 0.46
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
VDR P11473 4/20 0.45
NR1H4 Q96RI1 4/20 0.45
CPT1B Q92523 4/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
OPRM1 P35372 1/20 0.44
OPRD1 P41143 1/20 0.44
OPRK1 P41145 1/20 0.44
OPRL1 P41146 1/20 0.44
CPT2 P23786 4/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5511460 0.92 L3MBTL1 (0.48) L3MBTL1CPT1AACHEALDH1A1LMNA
SCHEMBL4131668 0.89 L3MBTL1 (0.45) L3MBTL1CPT1AACHEALDH1A1LMNA
SCHEMBL5515105 0.85 L3MBTL1 (0.48) L3MBTL1CPT1AACHEALDH1A1LMNA
SCHEMBL14613989 0.85 CYP2D6 (0.45) L3MBTL1CPT1AACHEALDH1A1LMNA
SCHEMBL5514473 0.84 L3MBTL1 (0.56) L3MBTL1VDRNR1H4
SCHEMBL14382778 0.83 OPRM1 (0.56) L3MBTL1VDRNR1H4OPRM1OPRD1
SCHEMBL13904453 0.83 L3MBTL1 (0.43) L3MBTL1CPT1AACHEALDH1A1LMNA
SCHEMBL5511472 0.82 L3MBTL1 (0.52) L3MBTL1CPT1AVDRNR1H4CPT1B
SCHEMBL27574019 0.82 L3MBTL1 (0.69) L3MBTL1OPRM1OPRD1OPRK1
SCHEMBL28746776 0.81 L3MBTL1 (0.58) L3MBTL1VDRNR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6770666-B2 A THERAPEUTIC AGENT FOR TREATING HEPATITIS C, BASED ON POLYMERASE INHIBITORY ACTIVITY JAPAN TOBACCO INC. (JP) 2004-08-03 US disclosed
US-20030050320-A1 Fused-ring compounds and use thereof as drugs JAPAN TOBACCO INC. (JP) 2003-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050320-A1 Fused-ring compounds and use thereof as drugs HAVCR2, ZC3HAV1, HLA-C L3MBTL1 4672/4885CPT1A 307/4885ACHE 4160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.